Stronger for Longer: Managing Chronic Active ABMR in Renal Allograft Recipients: A Care Team Forum®
Program Overview
“I felt guilty for losing the gift someone so preciously gave me,” Mary reflected, as she discussed the emotional turmoil she went through after losing a transplanted kidney to antibody-mediated rejection. Learn more from Mary as she shares her experience alongside a multidisciplinary expert panel, including a nephrologist, pharmacist, and pathologist as they discuss the latest data on the pathophysiology, diagnosis, and emerging therapies for chronic active ABMR in renal transplantation.
Transplantation, nephrology, general surgery, and internal medicine clinicians
Educational Objectives
Upon completion of this activity, participants should be better able to:
Describe the pathogenic processes involved in chronic active antibody-mediated rejection (ABMR) in kidney transplantation
Utilize Banff criteria when diagnosing chronic active ABMR in renal allograft recipients
Integrate available data on emerging therapies for patients with chronic active ABMR following kidney transplantation
Activity Faculty
Arjang Djamali, MD, MS, FACP, FASN
Professor, Medicine
Tufts University School of Medicine Chair, Department of Medicine
Maine Medical Center
Portland, ME
Benjamin Adam, MD, FRCPC
Laboratory Site Chief and Anatomical Pathology Divisional Director
University of Alberta Hospital Associate Professor, Department of Laboratory Medicine and Pathology Program Director, Renal and Transplantation Pathology Fellowship
University of Alberta Medical Lead, North Sector Clinical Trials and Research
Alberta Precision Laboratories
Walter C. Mackenzie Health Sciences Centre
Edmonton, Alberta, Canada
Ashley A. Vo, PharmD, FAST
Professor, Pediatrics
David Geffen School of Medicine at UCLA Director, Transplant Immunotherapy Program
Comprehensive Transplant Center
Cedars-Sinai Medical Center
Los Angeles, CA